PRPO

Precipio, Inc. [PRPO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PRPO Stock Summary

Earnings have grown 61.46% per last year.

The Moving Average Convergence Divergence (MACD) for PRPO recently turned positive (within last 10 days).

An RSI reading of 70 or higher indicates an overbought or overvalued condition.

Does not have any significance market cap ($9.14M)

Top 10 Correlated ETFs

PRPO

Top 10 Correlated Stocks

PRPO

In the News

PRPO Financial details

Company Rating

Market Cap

9.14M

Income

-5.86M

Revenue

14.42M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

15 May 2024

P/E

-0.88

Forward P/E

PEG

0.16

P/S

0.66

P/B

0.62

P/C

P/FCF

-1.55

Quick Ratio

0.56

Current Ratio

0.79

Debt / Equity

LT Debt / Equity

EPS (TTM)

-4.89

EPS next Y

EPS next Q

EPS this Y

-57.97%

EPS next Y

EPS next 5Y

EPS last 5Y

-37.29%

Revenue last 5Y

37.19%

Revenue Q/Q

15.81%

EPS Q/Q

-162.5%

SMA20

27.27%

SMA50

133.33%

SMA100

100%

Inst Own

Inst Trans

ROA

-48%

ROE

-63%

ROC

-0.67%

Gross Margin

37%

Oper. Margin

-73%

Profit Margin

-73%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

4.752-15.42

52W High

+4.63%

52W Low

+292.38%

RSI

Rel Volume

2.65

Avg Volume

6.86K

Volume

18.19K

Perf Week

43.73%

Perf Month

57.58%

Perf Quarter

155.2%

Perf Half Y

166.02%

Beta

1.252

Volatility

1.91%, 1.8%

Prev Close

-3.12%

Price

15.695

Change

-2.88%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 6.86K
Market Capitalization 9.14M
Employee 51
CEO Mr. Ilan Danieli
Headquarters New Haven,CT,US
IPO Date 2017-06-30
Website https://www.precipiodx.com

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.